Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on May 19, 2026. The filing discloses the entry into material definitive agreements involving the exchange of royalty interests for Series Q Perpetual Preferred Stock. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market.
Key Financial Metrics and Transaction Details
The filing details a debt-for-equity exchange transaction rather than standard operating financial results. No revenue, profit, or cash flow data is provided in this specific report.
- Total Debt Reduction: $22,700,000 in outstanding royalty interest balances were reduced.
- Preferred Stock Issued: 908 shares of Series Q Perpetual Preferred Stock were issued in total.
- Transaction Breakdown:
- Uptown Capital, LLC: Issued 500 shares in exchange for a $12,500,000 reduction of the December 2020 Royalty Interest.
- Streeterville Capital, LLC: Issued 148 shares for a $3,700,000 reduction and 260 shares for a $6,500,000 reduction of the August 2022 Royalty Interest.
- Stated Value: Each share of Series Q Preferred Stock has a stated value of $25,000.
- Preferred Return: Accrues at a rate of 10% per year, payable via the issuance of additional Series Q shares.
Material Changes and Terms
The primary material change is the conversion of royalty obligations into perpetual preferred equity, altering the Company's capital structure and future cash flow obligations.
- Liquidity and Redemption: The Series Q Preferred Stock is not convertible by the holder but is exchangeable or redeemable by the Company at its sole discretion for Common Stock, subject to specific conditions (e.g., 9.99% beneficial ownership cap).
- Liquidation Preference: Holders are entitled to the Stated Value plus accrued Preferred Return before Common Stockholders in a liquidation event. In a Chapter 7 bankruptcy, they share pari passu with Common Stockholders based on a floor price of $0.726 per share.
- Voting Rights: Shares vote on an as-converted basis with Common Stock, subject to a 9.99% voting cap per holder.
- Covenants: The Company is restricted from issuing equity securities with net proceeds exceeding $15,000,000, increasing authorized shares, or consummating a "Fundamental Transaction" (e.g., merger, sale of assets) without the consent of Required Holders.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking financial guidance or management commentary on future earnings.
- Liquidity Risk: There is no established trading market for the Series Q Preferred Stock, and the Company does not expect one to develop, limiting liquidity for these securities.
- Event of Default: Failure to comply with covenants, failure to pay amounts due, or bankruptcy proceedings constitute an Event of Default. This allows holders to force the Company to redeem shares for Common Stock (Forced Redemption Shares).
- Exchange Conditions: The Company cannot exchange preferred stock for common stock if it would cause a holder to exceed the 9.99% beneficial ownership limit or if the Common Stock is not listed on a Trading Market.
Investor Verification Checklist
- Verify the current outstanding balance of the December 2020 and August 2022 Royalty Interests post-transaction.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific definitions of "Minimum Price" and "Floor Price" impacting conversion ratios.
- Confirm the Company's ability to meet the 10% annual Preferred Return obligation, which compounds via share issuance.
- Assess the impact of the 9.99% beneficial ownership cap on the Company's ability to raise future capital or execute strategic transactions.
- Check for any existing defaults on the secured promissory notes mentioned in the Exchange Conditions (Streeterville notes from 2021 and 2025).